Cartesian Growth Corp II signs LOI with risk-reduction products target; 2025 EBITDA >$100M

Cartesian Growth Corp II

Non-binding LOI signed Oct 15 for initial business combination with a target in the risk-reduction products sector.
Pro forma target expected to be market-leading, multi-country operations, with >$100M 2025 adjusted EBITDA.
No guarantee of definitive agreement; subject to board/stakeholder approvals, regulatory conditions, and closing.
Company filed preliminary proxy on Oct 9 for shareholder meeting; investors urged to read proxy statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.